A recent Cardiology digest,
as sent to subscribers

Study Type: Prospective cohort study

Key Question: Does consumption of fructose-containing foods and beverages (SSBs, fruit juice, whole fruit) from childhood through adulthood affect incident hypertension risk?

Key Findings:

• SSBs (≥2 servings/day) and fruit juice (≥1.5 servings/day) were independently associated with higher hypertension risk (HR 1.52 [95% CI 1.27–1.83] and HR 1.35 [95% CI 1.06–1.71], respectively)
• Whole fruit intake showed no significant association with hypertension (HR 0.79 [95% CI 0.59–1.05])
• Substituting one daily SSB serving with whole fruit, milk, or water was associated with 22%, 13%, and 9% lower hypertension risk respectively

Clinical Relevance: Supports current NHS guidance limiting SSB and fruit juice consumption from childhood; fruit juice should not be considered a safe alternative to SSBs for cardiovascular risk reduction.

Limitations: Hypertension was self-reported, introducing potential misclassification bias.

Study Type: Scientific statement (expert consensus/narrative review — not original research)

Key Question: What is the current evidence base for perioperative anaemia assessment and patient blood management (PBM) strategies in cardiac surgery?

Key Findings:

• Up to 50% of patients presenting for cardiac surgery have preoperative anaemia, with iron deficiency identified as the most prevalent and modifiable cause
• PBM is framed as a multidisciplinary intervention targeting preoperative optimisation, intraoperative blood conservation, and reduced transfusion exposure to improve outcomes
• The statement identifies significant knowledge gaps and challenges in applying PBM consistently across specific patient subgroups

Clinical Relevance: With cardiac surgical volumes sustained across NHS centres, this AHA statement consolidates emerging evidence on iron deficiency treatment and blood conservation strategies directly relevant to preoperative assessment pathways and transfusion governance.

Limitations: As a consensus scientific statement rather than systematic review or meta-analysis, recommendations reflect expert synthesis and may not be graded by formal evidence hierarchy.

Study Type: Narrative review (commentary/overview — not original research)

Key Question: What are the current challenges and emerging directions in the pathogenesis, diagnosis, and management of large vessel vasculitis (giant cell arteritis and Takayasu arteritis)?

Key Findings:

• Diagnosis remains difficult due to nonspecific symptoms; advanced vascular imaging is emerging as a key diagnostic aid
• Novel immunotherapy agents targeting specific pathways offer potential to reduce reliance on glucocorticoids and their associated morbidity
• Molecular imaging may improve objective monitoring of disease activity and treatment response

Clinical Relevance: UK cardiologists managing aortopathy, unexplained aortic dilatation, or cardiovascular complications of systemic inflammation should be aware of evolving diagnostic and therapeutic strategies in LVV, particularly given its cardiovascular sequelae.

Limitations: As a narrative review, it is subject to selection bias in source literature and does not provide pooled quantitative data.

Study Type: Scientific statement / expert consensus (American Heart Association)

Key Question: How should heart failure with reduced or mildly reduced ejection fraction during pregnancy and the postpartum period be defined, diagnosed, and managed?

Key Findings:

• True incidence of perinatal heart failure is unknown; population prevalence estimates reach 1–2%, but obstetric-specific data are lacking
• Physiological changes of pregnancy (dyspnoea, oedema, fatigue) mask classic heart failure symptoms, contributing to diagnostic delay and adverse maternal outcomes
• Current evidence base is insufficient; the statement calls for standardised definitions, validated screening tools, and inclusion of pregnant/postpartum patients in heart failure trials

Clinical Relevance: UK cardiologists managing pregnant patients with cardiomyopathy face the same diagnostic ambiguity highlighted here; this statement provides a framework pending robust trial data, relevant to MDT working with obstetric teams.

Limitations: As a consensus statement rather than original research, recommendations are expert-opinion-driven with acknowledged absence of high-quality trial evidence in this population.

Study Type: Registry-based cohort study (prospective national quality registry)

Key Question: Does the AHA Target: AS registry identify gaps in upstream quality of care for patients with moderate or severe aortic stenosis?

Key Findings:

• Timely diagnosis improved from 54% (2023) to 61% (2024), but remained substantially incomplete, primarily due to absent multimodality testing (87% vs 75%) and delayed symptom assessment
• Timely AVR in those with a Class I indication was 82–85%, but ~40% of patients did not receive guideline-recommended surveillance echocardiography
• Clinical recommendations were included in echocardiogram reports less than 10% of the time, despite 83–85% documentation of key echo parameters

Clinical Relevance: UK cardiology teams managing valve disease through TAVI/surgical MDT pathways face similar upstream diagnostic delays; this registry highlights that echo reporting practice and surveillance scheduling are high-yield targets for quality improvement.

Limitations: Findings derive from self-selected US registry sites, limiting generalisability to broader or non-participating centres.

Study Type: Commentary / hypothesis paper (no original primary data)

Key Question: Does diastolic dysfunction represent an upstream shared pathophysiological driver of aortic stenosis initiation and progression, rather than a downstream consequence of valvular obstruction?

Key Findings:

• AI-derived diastolic dysfunction risk scores — generated without valve imaging — can predict future AS development even in patients with aortic sclerosis, challenging the conventional afterload-first model
• The authors propose a shared "mechano-inflammatory milieu" (arterial stiffness, elevated afterload, disrupted ventriculo-valvular-vascular coupling) detectable earlier in myocardium than valve tissue
• This framework reframes diastolic dysfunction as an early biomarker for calcific AS risk, potentially enabling intervention before significant valvular disease establishes

Clinical Relevance: If validated, this model could shift AS screening and early risk stratification toward routine echocardiographic diastolic assessment, relevant to current NHS valve surveillance pathways.

Limitations: Hypothesis-generating only; no primary outcome data presented to confirm causality.

Study Type: RCT (ad hoc analysis of PARTNER 3 — 7-year follow-up)

Key Question: Does balloon-expandable TAVR (SAPIEN 3) demonstrate comparable valve durability to surgical AVR at 7 years in low-risk patients with severe aortic stenosis?

Key Findings:

• SVD-related bioprosthetic valve dysfunction (stages 2–3), all-cause valve failure, and reintervention rates were low and statistically equivalent between TAVR and surgery (all-cause BVF: 6.9% vs 7.5%, HR 0.91, 95% CI 0.55–1.49)
• Thrombosis-related valve dysfunction was significantly more frequent with TAVR (5.2% vs 0.9%, HR 5.52, 95% CI 1.92–15.85), though most events occurred within 3 years and rarely progressed to valve failure
• Freedom from all-cause valve failure at 7 years was similar: 73.4% (TAVR) vs 74.8% (surgery)

Clinical Relevance: These data support TAVR as a durable medium-term option in low-risk patients, directly informing Heart Team discussions about valve choice in younger UK patients where longevity is a priority concern.

Limitations: Ad hoc analysis with ~20% echocardiographic attrition at 7 years, potentially introducing ascertainment bias for valve dysfunction outcomes.

Study Type: Narrative review / commentary

Key Question: Can RV-specific imaging and haemodynamic parameters serve as robust, validated end points in cardiovascular clinical trials?

Key Findings:

• RV metrics from echocardiography, CMR, CT, and right heart catheterisation show potential across HF, cardiomyopathies, valvular disease, pulmonary hypertension, and congenital heart disease, but are applied inconsistently across trials
• Major barriers include acquisition variability, incomplete data capture, absent standardised protocols, and lack of validated links between short-term RV changes and long-term clinical outcomes
• AI-assisted analysis and centralised data processing are identified as priority solutions to improve reproducibility in multicentre settings

Clinical Relevance: For UK cardiology triallists and clinicians managing RV-dependent conditions, adopting standardised RV end points could improve trial efficiency and mechanistic understanding, supporting faster regulatory and NICE appraisal pathways.

Limitations: As a narrative review without systematic methodology, conclusions reflect expert opinion rather than pooled quantitative evidence.